title: Serologic responses, biosafety and clearance of four dosages of Brucella abortus strain RB51 in 6-10 months old water buffalo (Bubalus bubalis).
abstract: Thirty water buffalo were obtained from a brucellosis-free farm in order to evaluate antibody responses, bacterial clearance and safety to Brucella abortus strain RB51 vaccine in a dose response study. The animals were randomly divided into five treatment groups. Groups I-V received the recommended dose of RB51 vaccine (RD) once, RD twice 4 weeks apart, double RD once, double RD twice 4 weeks apart and saline once, respectively. Antibody responses to RB51 were monitored at 2, 4, 6, 8, 10, 12, 16 18, 22, 24 and 27 post-initial-inoculation weeks (PIW). Clearance of RB51 from the prescapular lymph node was evaluated at 2, 4, 6, 12, 18 and 24 PIW for groups 1, III and V and at 6, 8, 10, 16, 22 and 27 PIW for groups II and IV. To evaluate shedding of the RB51 strain, nasal, conjunctival, vaginal or preputial swabs were taken from all experimental animals at 1, 2, 3, 4, 6, 8 and 12 PIW. Sera taken at all PIW were negative for field strain B. abortus by both the buffered plate agglutination test (BPAT) and competitive enzyme-linked immunosorbent assay (c-ELISA). Antibody responses to RB51 were demonstrated in all vaccinates but not in the controls, up to 12 PIW, by complement fixation test (CFT) and the dot-blot assay with an 83.7% agreement for both tests. Clearance of RB51 occurred between 6 and 12 PIW in group I but less than 2 weeks after booster vaccinations in groups II and IV and between 4 and 6 PIW in group III. RB51 was not recovered at any time from swabs obtained from either RB51-vaccinates or non-vaccinates. The results of this study indicate that serologic responses to RB51 vaccination can be monitored by both CFT and dot-blot assay in water buffalo. Our data also indicates that RB51 vaccination does not interfere with brucellosis sero-surveillance and is safe (no serological and bacteriological evidence of spread to non-vaccinates, no adverse clinical signs or detectable abnormalities on haematology and serum biochemistry) for use in water buffalo.
authors.affiliation: Faculty of Medical Sciences, School of Veterinary Medicine, University of the West Indies, Champs Fleurs, Trinidad and Tobago. michaeldiptee@hotmail.com
authors.forename: M D
authors.initials: MD
authors.lastname: Diptee
authors.forename: A A
authors.initials: AA
authors.lastname: Adesiyun
authors.forename: Z
authors.initials: Z
authors.lastname: Asgarali
authors.forename: M
authors.initials: M
authors.lastname: Campbell
authors.forename: R
authors.initials: R
authors.lastname: Adone
mesh_terms: D000372:Agglutination Tests / Q000662:veterinary; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D002004:Brucella Vaccine / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use; D002003:Brucella abortus / Q000276:immunology*; D002006:Brucellosis / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control / Q000662:veterinary*; D002020:Buffaloes / Q000276:immunology* / Q000382:microbiology*; D015169:Colony Count, Microbial / Q000662:veterinary; D003168:Complement Fixation Tests / Q000662:veterinary; D004306:Dose-Response Relationship, Immunologic; D004797:Enzyme-Linked Immunosorbent Assay / Q000662:veterinary; D005260:Female; D015151:Immunoblotting / Q000662:veterinary; D008198:Lymph Nodes / Q000382:microbiology; D008297:Male; D014611:Vaccination / Q000662:veterinary*; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use
chemical_list: D000907:Antibodies, Bacterial; D002004:Brucella Vaccine; D014613:Vaccines, Attenuated